Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Relay Therapeutics
Biotech
ESMO: Relay spotlights expanded FGFR2 data
Relay Therapeutics reported a nearly 90% response among patients in an expanded cohort of a trial testing the company's bile duct cancer med.
Max Bayer
Sep 11, 2022 12:03pm
IDRx nabs $122M to address precision medicine 'whack-a-mole'
Aug 2, 2022 6:30am
Relay poaches AstraZeneca, bluebird bio R&D execs
May 3, 2021 8:50am
The top 10 biotech IPOs of 2020
Feb 16, 2021 3:00am
Genentech pays Relay $75M for cancer drug, plans KRAS combo
Dec 14, 2020 8:42am
Relay passes the baton from private to public biotech for $400M
Jul 16, 2020 9:30am
